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Human GPR42 is a transcribed 
multisite variant that exhibits 
copy number polymorphism and 
is functional when heterologously 
expressed
Henry L. Puhl III, Yu-Jin Won†, Van B. Lu & Stephen R. Ikeda
FFAR3 (GPR41) is a G-protein coupled receptor for which short-chain fatty acids serve as endogenous 
ligands. The receptor is found on gut enteroendocrine L-cells, pancreatic β-cells, and sympathetic 
neurons, and is implicated in obesity, diabetes, allergic airway disease, and altered immune function. 
In primates, FFAR3 is segmentally duplicated resulting in GPR42, a gene currently classified as a 
suspected pseudogene. In this study, we sequenced FFAR3 and GPR42 open reading frames from 
56 individuals and found an unexpectedly high frequency of polymorphisms contributing to several 
complex haplotypes. We also identified a frequent (18.8%) structural variation that results in GPR42 
copy number polymorphism. Finally, sequencing revealed that 50.6% of GPR42 haplotypes differed 
from FFAR3 by only a single non-synonymous substitution and that the GPR42 reference sequence 
matched only 4.4% of the alleles. Sequencing of cDNA from human sympathetic ganglia and 
colon revealed processed transcripts matching the GPR42 genotype. Expression of several GPR42 
haplotypes in rat sympathetic neurons revealed diverse pharmacological phenotypes that differed 
in potency and efficacy. Our data suggest that GPR42 be reclassified as a functioning gene and that 
recognition of sequence and copy number polymorphism of the FFAR3/GPR42 complex be considered 
during genetic and pharmacological investigation of these receptors.
Free fatty acid receptors (FFAR) are a family of seven trans-membrane spanning G-protein coupled recep-
tors (GPCR) that utilize free fatty acids as endogenous agonists. FFAR2 and FFAR3 utilize short-chain 
fatty acids (SCFA) with 2–4 carbons (acetate, C2; propionate, C3; butyrate, C4) as ligands while FFA1 
and FFA4 require longer chain fatty acids (C8–C22) for activation1. FFAR2 and FFAR3, originally termed 
GPR43 and GPR41, respectively, were de-orphanized in 2003 by two groups working independently2,3. 
Both FFAR2 and FFAR3 are heavily expressed in enteroendocrine cells (primarily I- and L-cells) of the 
distal small intestine and proximal large intestine where bacterial fermentation of soluble fiber provides 
a source of SCFAs at concentrations sufficient to activate these relatively low affinity receptors. Recently, 
the composition of the gut microbial community, or microbiota, have been shown to influence metabolic 
physiology at least partially via mechanisms dependent on FFAR24 and FFAR35–7. FFAR3 is also impli-
cated in allergic airway disease8, diabetes9, and immune function10. At sites remote from the gut lumen 
and associated vasculature (e.g., the hepatic portal vein), plasma concentrations of SCFAs are maintained 
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at lower levels in non-ruminants and thus mechanisms of endogenous receptor activation are less clear. 
For example, FFAR3 is expressed in postganglionic sympathetic neurons distant from the gut lumen and 
the ketone body, β -hydroxybutyrate (BHB), has been put forth as a potential endogenous ligand11–13. In 
addition, oxidative metabolism of ethanol in humans14,15 results in a pharmacological source of plasma 
C2 at concentrations potentially relevant to FFAR2/FFAR3 receptor activation.
Extrapolating the role of FFAR3 from rodents to humans is complicated by two factors. First, mouse 
FFAR3, which is about 80% similar to human FFAR3, displays distinctive pharmacological profiles16. 
Second, a tandem segmental duplication of the genomic region containing the open reading frame (ORF) 
of FFAR317 is present in primates but not other mammals. The duplicated FFAR3 ORF, termed GPR42 
in humans, was originally declared a pseudogene based on a lack of functional activity when the GPR42 
ORF (Genbank: NG_008348), which is contained within a single exon, was heterologously expressed in 
various yeast and mammalian systems2. The predicted protein product for GPR42 varied by six amino 
acids from FFAR3 with the R174W substitution determined as critical for ablating GPR42 function. 
The designation of GPR42 as a nonfunctioning pseudogene and the lack of an equivalent duplication in 
rodents suppressed further study. However, a detailed study of GPR42 ORF variation using restriction 
enzyme polymorphism analysis of amplified genomic regions demonstrated that the R174W substitution 
occurred in only 39% of GPR42 ORFs18. Moreover, sequencing of selected FFAR3 and GPR42 ORFs 
showed variations at 5 of 6 positions differing from the Genbank reference sequences. This work thus 
raised the question of whether the GPR42 ORF was a pseudogene and pointed out the potential uncer-
tainty in determining FFAR3 or GPR42 genomic sequences due to the high degree of sequence identity 
between the two regions harboring the ORFs. It was also emphasized that standard techniques used 
for determining mRNA expression, including Northern blot analysis, TaqMan, and RT-PCR would be 
unlikely to discriminate between transcripts arising from FFAR3 and GPR4218.
In this study, we wished to determine whether GPR42 is properly classified as a pseudogene or should 
be reclassified as a functional gene. To this end, we examined three different aspects of GPR42 gene struc-
ture and function. First, we extended the work of Liaw and Connolly18 by amplifying specific genomic 
regions containing FFAR3 and GPR42 ORFs from fifty six individuals, cloning individual alleles, and 
sequencing the ORFs for FFAR3 and GPR42. Our results indicate that both FFAR3 and GPR42 are highly 
polymorphic with numerous positions yielding minor allele frequencies greater than 30%. Moreover, the 
majority of GPR42 ORFs lacked the R174W substitution and were thus predicted to be functional. None 
of the ORFs examined contained frame-shifting indels or premature stop codons. Second, we amplified 
mRNA from human sympathetic ganglia and colon and identified cDNA sequences that originated from 
GPR42 alleles. Finally, we heterologously expressed several of the human GPR42 ORFs in rat sympathetic 
neurons and demonstrated functional coupling to N-type Ca2+ channels following application of agonist. 
Taken together, these results provide evidence that human GPR42 is both transcribed and potentially 
produces a functional protein. Thus, the status of GPR42 should be changed from pseudogene to func-
tional and the gene product(s) of GPR42 assigned to a member of the FFA receptor family.
Results
The human gene for FFAR3 resides at chromosomal locus 19q13.1 between FFAR1 (GPR40) and FFAR2 
(GPR43). This syntenic relationship appears preserved in most mammals suggesting that the gene fam-
ily arose from an ancient gene duplication event. Starting with primates, however, a tandem segmental 
duplication of a 12.5 kb piece encompassing both FFAR1 and FFAR3 is present. A Pustell DNA matrix 
dot plot (Fig.  1A) of human chromosome 19 region 35839496:35865083 (GRCh37/hg19) illustrates 
the duplicated segments (black and gray bar; bottom) and, within these segments, two smaller regions 
(denoted region 1 and 2 in Fig. 1A) have retained a high degree of sequence identity (> 90%). Region 
1 (dark blue bar) resides primarily upstream to the open reading frame (ORF) of FFAR1 and extends 
about 46 bases into the ORF (Fig. 1B;18). Hence, the Region 1 duplicon (region 1 dup) may retain FFAR1 
promoter elements but is not predicted to code for a functional protein. The function of this region and 
the evolutionary pressure maintained to conserve sequence identity is unknown. Conversely, region 2 
(purple bar) encompasses both exon 1 and 2 of FFAR3. Therefore, the region 2 duplicon (red bar), which 
retains extremely high sequence identity (≈ 98%) for about 2.5 kb, includes the entire ORF and 3′ -UTR 
containing exon, an upstream exon encoding most of the 5′ -UTR, and an additional 500 bp of the puta-
tive upstream intragenic region that may contain a promoter region (Fig. 1B, red elements). The ORF in 
the region 2 duplicon is sometimes denoted GPR42p (we will use GPR42 hereafter) based on the lack of 
functional activity of the heterologously expressed GPR42 reference sequence (Genbank: NG_008348) in 
cellular assays2. However, the seminal work by Liaw and Connolly18 provide evidence that the reference 
sequence for GPR42 may not be representative of the population examined (not specified) in that study. 
Because of the very high sequence identity in FFAR3/GPR42 regions, most short read high-throughput 
technologies are unable to reliably assign sequences to these regions as illustrated in the accessible region 
mask (1 K genomes project, phase 1) depicted in Fig. 1C. Therefore, little is known about the sequence 
variability of either the FFAR3 or GPR42 ORF on a population basis.
To address this question, we adapted the methodology of Liaw and Connolly18 to sequence the FFAR3 
and GPR42 ORFs from the genomic DNA of 56 individuals. Briefly, PCR amplicons of the FFAR3 
(1.98 kb) and GPR42 (1.78 kb) ORF were generated with a high fidelity polymerase from primers tar-
geted to unique regions upstream of the respective ORFs (Fig. 1B, purple and red balls) plus a common 
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downstream primer (Fig. 1B, cyan ball). PCR products were subcloned and DNA from 5–8 individual 
colonies sequenced to determine allelic variation.
Sequence of the FFAR3 open reading frame. Initial results from FFAR3 and GPR42 sequencing 
revealed an unexpected degree of variation so nucleotides positions within the ORF that varied from the 
FFAR3 reference sequence (Genbank: NM_005304) were assigned an index value to facilitate sorting. A 
table listing the assigned index position, nucleotide position (relative to the A of the start codon), residue 
number with codon position, and amino acid change, if any, are show in figure S1A. The affected resi-
dues shown in a GPCR snake diagram are illustrated in figure S1B. All affected positions were bi-allelic.
Figure S2A depicts the sequencing results for FFAR3 from 56 individuals. The y-axis represents the 
SNP index position described in Fig. S1A. The x-axis represents alleles with adjacent columns repre-
senting the same individual. The first 50 individuals were sequenced from an existing gDNA sample 
cohort (B01–B50). The next 5 individuals (alleles 100–109) were sequenced from gDNA isolated from 
sympathetic ganglia obtained from the NDRI for which cDNA was also sequenced (CG01–05). The final 
sample was obtained from an NDRI human colon sample (C01). Each filled block represents a deviation 
from the FFAR3 reference sequence. To visualize individual isoforms, each column (allele) was converted 
to a 23-bit unsigned integer based on a position index (a variation from the reference sequence consid-
ered as a 1) and sorted with the most frequent isoforms to the left. Isoform nomenclature was based on 
frequency and grouping with synonymous isoforms receiving a sub-designation.
From this analysis (Fig.  2B,C), we see that the reference protein sequence (denoted 41.1; Genbank: 
NP_005925) represented about 30% of the alleles. Isoforms 41.2–41.4 comprise an additional 53% of the 
sequences with each possessing a single non-synonymous mutation and, for 41.3, two additional syn-
onymous variations. The remaining variants were manually grouped based on sequence characteristics. 
Group 1 consists of variants with polymorphisms not found in GPR42. The main variant in this group, 
41.5, contained the D158N substitution (Fig.  2A, orange bar) that mutagenesis studies indicate results 
Figure 1. Tandem segmental duplication of FFAR1 and FFAR3. (A) Dot plot of a 25.6 kb region from 
human chromosome 19. The plot was generated with a Pustell DNA Matrix (scoring matrix DNA identity, 
window size of 30, similarity 90%) in MacVector version 13.5. Diagonals represent regions of sequence 
identity (the self identity diagonal was removed for clarity) and projected to the abscissa (colored bars). 
The black and gray bars (bottom) represent the presumed original 12.5 kb duplication. (B) Annotation of 
genes and primers. Colored arrows represent genes with the white bar depicting the open reading frame. 
FFAR1, FFAR3 and GPR42 are shown in blue, purple, and red, respectively. The small portion of FFAR1 
retained in the duplicated region is labeled as FFAR1 fragment (blue bar). Location of primers used for 
PCR amplification of FFAR3 and GPR42 ORFs are shown as balls above the sequence map along with the 
predicted amplicon length. (C) Composite accessible region mask from 1000 genomes phase 1. The filled 
area represents regions accessible to accurate analysis with short read sequencing.
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in increased constitutive activity19. Group 2 consists of variants with alterations at positions that were 
common in GPR42. The 41.8 variant contains the R174W substitution (Fig.  2A, red bar) that is pre-
dicted from earlier studies to severely decrease efficacy2. Finally, group 3 isoforms all possess the S346N 
variation that was present in every GPR42 allele we sequenced (see below). The 41.9 variant has the 
same predicted protein sequence as the most common GPR42 variant although it contains an additional 
synonymous polymorphism not present in GPR42 (see below). These data show an increased frequency 
of genetic variability in the FFAR3 with several non-synonymous variations predicted to affect receptor 
function.
A structural variation produces copy number polymorphism in GPR42. During the course of 
this study, we began to suspect a variation in the copy number of GPR42 based on the following lines of 
evidence. First, in the original description of the human GPR40–4317, a cosmid clone (Genbank: U62631) 
was identified that was missing GPR42 but contained downstream flanking sequence. The authors there-
fore suggested that GPR42 might represent a polymorphic insert. Second, Liaw and Connolly18 analyzed 
206 vs. 204 alleles for FFAR3 and GPR42, respectively, although offered no explanation for the mismatch. 
Similarly, in the course of this study we encountered a single genomic sample, denoted B02, from which 
we were unable to amplify GPR42 despite repeated attempts with different primer sets. Finally, exami-
nation of 1000 Genomes data20 with the UCSC Genome Browser21 for the region between FFAR3 and 
GPR42 revealed an approximately 12.5 kb deletion (dbVar: esv2678346; Fig. 3A1) based on read depth 
analysis that was present in 18.5% of the Phase 1 data. A more detailed examination of these data reveals 
a large variation in the deletion frequency among different ethnic groups (Fig. S3). For example, the 
deletion was completely absent in two African populations (LWK and YRI) while in the British cohort 
(GBR), 11.4 and 40.9% were homozygous and heterozygous, respectively, for the deletion. Despite this 
evidence, the presence of the deletion has not been directly validated to our knowledge. Accordingly, we 
examined whether the predicted deletion was present in the cohort under study.
A PCR-based test using two primer sets is shown in Figs 3A1-A2. One primer set (red and cyan balls) 
was designed to generate a ≈ 1.8 kb amplicon if GPR42 was present. A second set (purples and black) 
Figure 2. Sequence of FFAR3 alleles. (A) Raster diagram of FFAR3 ORF sequences from a cohort of 56 
individuals. Each row represents a SNP index position as defined in Fig. S1A. A column represents one of 
the alleles sequenced from each individual. A filled box represents an alteration from the FFAR3 reference 
sequence (Genbank: NM_005304). Black and gray fills represent non-synonymous and synonymous 
polymorphisms, respectively. Orange fill (D158N) represents a polymorphism that affects constitutive 
receptor activity. Red fill (R174W) represents a polymorphism associated with decreased receptor activity. 
The columns have been sorted by haplotype (the unsorted columns are shown in Fig. S2A). Pastel colors 
correspond to groupings shown in panels B and C. (B) Pie chart showing fractional representation of the 
major haplotypes and groups of related haplotypes. (C) Table of FFAR3 variants.
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flanked both FFAR3 and GPR42 and was predicted to generate a ≈ 3.3 kb amplicon when the deletion 
was present (Fig. 3A2). Note that the exact boundaries of the deletion were unknown but, assuming the 
deletion occurred via non-allelic homologous recombination (NAHR), should fall somewhere within 
the region 2/region 2 duplicon (Fig. 1A). DNA samples from a Finnish cohort (FIN) used in the 1000 
Genomes Phase 1 project were obtained and samples containing no deletion (+ /+ ), a single deletion 
(+ /− ), or both deletions (−/−) were used to validate the PCR-based test. As predicted, the + /+ samples 
displayed only the 1.8 kb band, the + /− samples both 1.8 and 3.3 kb bands, and the − /− samples only 
the 3.3 kb band (Fig. 3B). Note that the sole sample from our cohort, B02, that failed to produce a GPR42 
amplicon appears to be homozygous for the deletion. Sequencing the 3.3 kb PCR fragment confirmed 
the deletion model shown in Fig. 3A2.
An alternative, higher throughput, assay for the deletion based on the TaqMan™ Copy Number Assay 
(ABI) was run on three of the samples examined in Fig. 3B. The location of the qPCR primer/probe set 
(Chr.19:35852061) is shown in Fig. 3A1 (blue ball). The probe site lies outside of the sequence homol-
ogy domain and thus should be absent if the deletion arose from NAHR. The calculated copy number 
(based on CopyCaller™ v2.0 software, ABI) from the qPCR reaction (Fig. 3C) agreed with the PCR assay 
(Fig. 3B) and 1000 Genomes data. Thus the assay was run for the 56 samples in our cohort as illustrated 
in Fig. 3D. The results indicated that one individual, B02, was homozygous for the deletion and thus a 
Figure 3. GPR42 copy number polymorphism resulting from a 12.5 kb deletion. (A1) Gene map as 
shown in Fig. 1B with the deletion structural variation (dbVar: esv2678346) shown as a green bar. A PCR 
primer set used to detect the deletion is shown (purple and black balls). The predicted amplicon of 15.8 kb 
was not produced with the experimental conditions employed when GPR42 was present. TaqMan® copy 
number qPCR primer location is indicated with the blue ball. (A2) Gene map following deletion of the 
12.5 kb sequence. The exact boundaries of the deletion are assumed to be a homologous sequence within 
region 2 and the region 2 duplicon (Fig. 1A,B). An amplicon of 3.3 kb was produced when the deletion was 
present. (B) Exemplar agarose gel showing PCR amplicons produced with the GPR42 primer set (red and 
green primers; top gel) and the deletion detection primer set (purple and black primers; bottom gel). A 
non-specific product was present in the bottom gel below the 2 kb maker. Lanes 1–6 were amplified from 
gDNA from 1000 genomes Finnish cohort samples (ID below gel). Note that the 1000 genomes identifier 
format, HG00###, was altered to F### for brevity. The deletion genotype determined from read depth is 
shown above the gel image. B02 was the sole sample from our cohort for which the GPR42 ORF could not 
be amplified. (C) Validation of TaqMan® copy number qPCR assay using Finnish samples. Each sample 
was repeated 4 times. Mean copy number (error bars represent sample range) was calculated with ABI 
CopyCaller™ software. (D) Deletion copy number for 56 gDNA samples used in this study. The HDRI colon 
sample is denoted C01. Light and dark gray bars indicate a copy number of one and two, respectively, as 
determined by the software.
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predicted knockout of GPR42. Nineteen individuals were heterozygous for the deletion (light gray bars) 
and thus hemizygotic for GPR42. In summary, 21/112 alleles (18.8%) were positive for the deletion; a 
result similar to the overall 1000 Genomes Phase 1 data (18.5%).
Sequence of the GPR42 open reading frame. Sequencing of GPR42 was carried out with the same 
techniques used to sequence FFAR3. The majority of the sequencing was completed prior to discover-
ing the deletion. Except for one clone, all individuals identified with the copy number assay as GPR42 
hemizygotes were previously assigned to be homozygous (i.e., all clones tested had identical sequences). 
In figure S2B, we denote the deleted allele as a yellow column. Because the sequences were not phased, 
the deleted allele was arbitrarily assigned to the second column for each individual. The sequencing 
data shown in figure S2B are presented in comparison with the FFAR3 reference sequence (Genbank: 
NM_005304) as in Fig. S2A and show a high degree of variation.
The individual GPR42 haplotypes became more apparent after sorting the data (Fig.  4A) as done 
earlier (Fig.  2A). The deletion, which affected the copy number of GPR42, is depicted as gray stripes 
and comprised 18.8% of the potential alleles. Of the GPR42 alleles sequenced, 50.5% (haplotypes 42.1.1–
42.1.3; Fig.  4C, second frequency column) predict a translation product that differed from the FFAR3 
reference sequence by a single alteration in the last amino acid (S346N). The next block of haplotypes, 
denoted Group 1 (Fig. 4, green), constitute 31.9% of the sequenced alleles. All Group 1 variants contained 
the R174W variation (red bar in Fig. 4A) implicated in decreased function and consequent assignment 
of GPR42 to pseudogene status. Most haplotypes in this group were similar to the GPR42 references 
sequence (Genbank: AF024689) which consists of six non-synonymous polymorphisms (Q44R/R45C/
R174W/L227V/A256V/S346N). It should be noted that the reference sequence, denoted here as haplo-
type 42.3, comprises just 4.4% of the alleles sequenced. The Group 2 haplotypes (6.6%; yellow) contained 
some elements found in Group 1 but did not contain the R174W variation. The remaining haplotypes 
(11%) were assigned to Group 3 (orange) and contained unique variations not found in the FFAR3 hap-
lotypes. All of the GPR42 haplotypes sequenced contained the S346N variation.
These data indicate that the GPR42 ORF sequence is highly heterogeneous within this population and 
that very few alleles matched the current reference sequence for this gene. Moreover, the vast majority 
of the haplotypes did not possess the R174W variation that was predicted to produce functional impair-
ment and thus assignment of GPR42 to pseudogene status.
Figure 4. Sequence of GPR42 alleles. (A) Raster diagram of GPR42 ORF sequences from a cohort of 
56 individuals. Row and columns are as in Fig. 2A. The striped gray group represents deleted alleles 
as determined in Fig. 3. Pastel colors correspond to groupings shown in panels B and C. (B) Pie chart 
showing fractional representation of the major haplotypes and groups of related haplotypes. (C) Table of 
GPR42 variants. The first frequency column was calculated including the deletion (total = 112). The second 
frequency column was calculated from sequenced variants (total = 91).
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GPR42 transcript in sympathetic neurons and colon. Although the sequence of GPR42 ORF was 
highly variable, we did not encounter overt deleterious variations such as frame shift deletions/insertions 
or premature stop codons. In the cohort sequenced, 50.6% of GPR42 ORFs predicted a protein product 
that varied from FFAR3 by only a single amino acid in the terminal position thus undermining previous 
reasoning for assigning GPR42 to pseudogene status. We thus sought to determine whether mRNA for 
GPR42 was transcribed.
Two factors made detection of GPR42 message challenging. First, the lack of GPR42 in rodents neces-
sitated using human tissue where the distribution of FFAR3 is incompletely characterized. We choose 
abdominal sympathetic ganglia11 and colon22 as potential sources of GPR42 message assuming similarity 
with the FFAR3 expression pattern. Second, because of the high sequence similarity between FFAR3 
and GPR42, standard methods of determining mRNA (e.g., Northern blots, TaqMAN qPCR, RT-PCR) 
would not discriminate between the two gene products18. The approach we used was to couple gDNA 
sequencing of FFAR3/GPR42 alleles, as performed above, with mRNA isolation, reverse transcription, 
and sequencing of multiple cDNA clones. This allowed unambiguous matching of cDNA sequences to 
gDNA alleles. Amplicons from RT-PCR of cDNA isolated from human celiac-superior mesenteric gan-
glia samples are shown in Fig. 5A. Due to the high degree of sequence identity, the primers used were 
predicted to generate a 1.13 kb amplicon for both FFAR3 and GPR42 (Fig. 5A; lane 1). An 859 bp ampli-
con for tyrosine hydroxylase (Fig.  5A, lane 2), a marker specific for catecholaminergic neurons, and a 
981 bp amplicon (Fig. 5A, lane 3) for β -actin, a general marker, were examined to assess tissue identifi-
cation and RNA quality. Primers for FFAR3/GPR42 spanned a 230 bp intron that allowed unambiguous 
Figure 5. GPR42 transcription. (A) Exemplar agarose gel depicting RT-PCR products amplified from 
human celiac-superior mesenteric ganglia. FFAR3/GPR42: 1.13 kb amplicon that spans the intron between 
exon 1 and 2. TH: 859 bp amplicon for tyrosine hydroxylase, a marker specific for catecholaminergic 
neurons. β -actin: 981 bp amplicon for β -actin. (B1) Example of sequencing electropherogram for FFAR3/
GPR42 cDNA clone showing the splice junction between exon 1 and 2. (B2) Sequencing electropherogram 
for FFAR3/GPR42 clone in which the intron between exon 1 and 2 was retained. Sequences with the intron 
were not included in analyses. The black triangle represents the first position of the start codon. (C) SNP 
frequency for each index position. FFAR3 and GPR42 SNP frequencies were calculated for 112 and 91 
alleles, respectively. The latter number accounts for the GPR42 deletions. SNP position is for nucleotide 
position within the ORF. Corresponding amino acid positions are shown in Fig. S1A. (D) Exemplar 
sequences from the Illumina Body Map 2.0 colon RNA-seq data set (www.ensembl.info/blog/2011/05/24/
human-bodymap-2-0-data-from-il) showing several A919G reads (red; 5/18 transcripts assigned to this 
region were A919G). In our data, A919G was frequently found in GPR42 (30.8%) but never found in 
FFAR3.
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identification of sequence originating from processed transcript (Fig. 5B1) versus gDNA or unprocessed 
transcript (Fig. 5B2). Sequences of cDNA containing the intron were excluded from analysis.
The sequences for gDNA isolated from the celiac-superior mesenteric ganglia are shown in Fig. S2 
(alleles 100–110) and the copy number for GPR42 in Fig. 3D (CG01–05). RNA of sufficient quality for 
subsequent analysis was isolated from CG02–05. The sequencing results for cDNA clones were variable. 
In one sample, CG05 (0/36), no evidence for GPR42 was found. Conversely, in CG02 (1/30), CG03 
(1/30), and CG04 (12/60), sequencing of cDNA clones were in full agreements with at least one of the 
gDNA GPR42 alleles. We also attempted a similar experiment with pre-existing human colon samples 
(obtained from NDRI). Of three colon samples, RNA of sufficient quality was isolated from just one. 
However, in this sample, 16/34 cDNA clones were consistent with a GPR42 allele. Taken together, these 
data suggest that GPR42 is transcribed in both sympathetic neurons and colon.
In addition to direct sequencing from human tissue, we sought additional evidence for transcription 
of GPR42 in RNA-Seq databases. As mentioned earlier, most short read next generation sequencing 
(NGS) techniques have difficulty assigning reads for segmentally duplicated genes with long stretches of 
nearly identical sequence23. However, several variant positions were relatively common amongst GPR42 
haplotypes in our cohort (e.g., 679(14), 880(19), and 919(20)) but never present in FFAR3 (Fig.  5C). 
Another potential marker was the G1037A (S346S) variation which was present in all GPR42 sequences 
but only rarely (6.4%) seen in FFAR3. Using this information, we found that A919G, a variant found 
in 30.8% (28/91) of GPR42 alleles but 0% (0/112) of FFAR3 alleles, was present in the Illumina Body 
Map 2.0 colon RNA-seq study (Fig. 5D). Note that sequences were assigned to both FFAR3 and GPR42 
suggesting errors in assignment due to the high degree of sequence identity.
Heterologous expression and function of GPR42 in rat sympathetic neurons. Finally, we 
examined whether several of the GPR42 haplotypes were functional when heterologously expressed. The 
model system (Fig. 6A) used was comprised of sympathetic neurons isolated from rat superior cervical 
ganglion intranuclearly injected with cDNA encoding an FFAR3 or GPR42 ORF. Following overnight 
incubation, receptor efficacy and potency were evaluated using inhibition of Ca2+ currents, determined 
from whole-cell patch clamp recordings, as the readout24. The system had two main advantages. First, we 
have extensively characterized both heterologous and native expression of FFAR3/FFAR2 in rat sympa-
thetic neurons12. Second, activation of endogenous FFAR3 in the sympathetic nervous system is poten-
tially important for a variety of physiological functions12,25.
An exemplar of the time course and current traces from the assay is illustrated in Fig. 6B,C, respec-
tively, for an SCG neuron expressing the reference FFAR3 (GPR41.1) ORF. Ca2+ currents, arising pri-
marily from N-type (CaV2.2) channels26, were evoked with the voltage protocol illustrated in Fig.  6C 
(bottom). The percent inhibition of the current in the first test pulse (Fig.  6B,C; filled circle) in the 
presence of agonist (C3) provides the data for the concentration response curves (Fig. 6D) and maximal 
efficacy plot (Fig.  6E). The time course reveals the rapid onset and recovery of response characteristic 
of lower affinity GPCRs in this system27,28. The similarity of response to the first and last maximal con-
centration application indicate minimal tachyphylaxis to propionate. Also plotted in Fig. 6B (lower), the 
facilitation ratio or postpulse/prepulse amplitude ratio shows an increase during propionate application. 
This form of voltage-dependent inhibition is characteristic of Ca2+ channel modulation mediated by 
Gβ γ 24,29–31.
The concentration-response curves (Fig.  6D) illustrate the mean prepulse Ca2+ current inhibition 
for the labeled haplotypes versus log [C3 μ M]. Expression of the reference FFAR3 sequence (41.1; pur-
ple filled circles) and the most abundant GPR42 sequence (42.1.1; S346N; red filled squares) produced 
similar results. The mean (95% CI range) EC50s for C3 were 11.1 (8.6–14.3) and 14.7 (10.5–20.4) μ M, 
respectively. Conversely, haplotypes 42.2 (red filled triangle) and 42.3 (red inverted triangle; the current 
GPR42 reference sequence) exhibited decreased potency with EC50s for C3 of 65.9 (38.2–114) and 73.4 
(53.8–100) μ M, respectively. The maximal efficacy for Ca2+ current inhibition, determined during 1 mM 
C3 application, is illustrated in Fig.  6E. Application of 1 mM C3 to control neurons (i.e., not injected 
with cDNA) produced a small mean inhibition (8.3 ± 1.1%; n = 12) consistent with previous results12 
suggesting a low endogenous expression of FFAR3. Similar maximal Ca2+ current inhibition was seen 
when expressing 41.1 (66.7 ± 2.7; n = 10), 42.1 (69.1 ± 2.9; n = 10), 42.2 (64.4 ± 4.1; n = 10), and 42.3 
(69.6 ± 2.5; n = 13). Note that both haplotypes 42.2 and 42.3 contain the R174W substitution that was 
previously shown to result in a null phenotype2. A fourth GPR42 haplotype, 42.9 (red filled diamonds), 
produced a small inhibition (9.1 ± 1.3%; n = 10) that was not significantly different from the control.
Taken together with the evidence for transcription of GPR42 (Fig. 5), these results suggest that at least 
half of the GPR42 haplotypes sequenced (42.1.1–42.1.3) would result in a functional protein. Moreover, 
haplotypes containing the R174W, including the current GPR42 reference sequence (42.3), were shown 
to have decreased potency when compared with FFAR3 (41.1) but equivalent efficacy. Thus, the great 
majority of GPR42 haplotypes would be predicted to be functional.
Discussion
Although the impact of FFAR3 and GPR42 on human physiology remains to be clarified, there is suffi-
ciently promising rodent data to promote development of pharmacological agents that act on FFAR332–34. 
For most Group A GPCRs, the ORF variant landscape is well defined due to efforts such as the 1000 
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Genomes initiative35. For example, FFAR2, from 1000 Genomes data, has two non-synonymous variants 
with a global minor allele frequency (MAF) of 1% or greater (dbSNP: rs409093, 4.8%; rs73931123, 1%) 
while FFAR1 has one (dbSNP: rs2301151, 12%). These frequencies are in general agreement with the 
“one SNP (> 1%) per 1000 bp of sequence” estimate of global human sequence variation36. As described 
earlier, the tandem segmental duplication of FFAR3 in primates and the persistence of high sequence 
identity with the duplicated GPR42 ORF confounds short-read NGS sequencing efforts. Hence, only the 
reference sequence for FFAR3 (Genbank: NP_005295) is examined in most in vitro studies. Our data 
expose a complex genetic picture with high variability in both FFAR3 and GPR42 ORFs, copy number 
polymorphism in GPR42 resulting from a frequent structural variation, and evidence for reclassifying 
GPR42 from a pseudogene to a functional gene.
Evidence supporting GPR42 as a functional gene. GPR42 was originally classified as a pseu-
dogene based on non-functionality when the reference ORF was expressed in model systems2. A sub-
sequent study18, however, revealed that the majority (61%) of GPR42 alleles examined did not possess 
the R174W polymorphism implicated in the inactive phenotype and thus questioned the pseudogene 
Figure 6. Function of GPR42 haplotype variants. (A) Schematic of the electrophysiological assay. FFAR3/
GPR42 were expressed in isolated rat superior cervical ganglion (SCG) neurons by intranuclear injection of 
mammalian expression vectors containing the ORF. After about 18 hours, whole-cell patch-clamp recordings 
in solutions designed to isolate Ca2+ currents were performed. Multiple concentrations of propionate (C3) 
were applied to the neuron via a multi-bore perfusion device. Activation of FFAR3/GPR42 produced an 
inhibition of the Ca2+ current. (B,C) Exemplar time course and current recording traces of a concentration-
response protocol. Ca2+ currents were evoked with the voltage protocol shown in C (bottom) at 0.1 Hz. 
Prepulse (filled circles, first epoch to + 10 mV) and postpulse (open circles, second epoch to + 10 mV) Ca2+ 
current amplitudes were plotted versus time (B, top). Application of C3 at the indicated concentration 
is shown as solid bars (B, middle). The postpulse to prepulse amplitude ratio (B, bottom) is a parameter 
related to voltage-dependent modulation; an indicator of Gβ γ inhibition. Superimposed current traces 
for 1, 10, and 100 μ M C3 application are shown in C. The larger current was acquired just prior to the 
C3 application. (D) Concentration response curves for FFAR3 (41.1; purple filled squares) and GPR42 
haplotypes (red filled symbols; 42.1 squares, 42.2 triangles, 42.3 inverted triangles). Mean (± SEM; N varies 
from 4–13) prepulse Ca2+ current inhibition (%) versus log [C3 μ M]. Solid lines represent non-linear 
regression fits to a single site binding isotherm (see Methods). (E). Category scatter plot (efficacy) for Ca2+ 
current inhibition during 1 mM C3 application). Mean (± SEM) Ca2+ current inhibition are superimposed 
on individual determinations. Control neurons were not injected with cDNA. Each category represents a 
different FFAR3/GPR42 haplotype as labeled.
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characterization. Our data indicate that GPR42 should be re-categorized as a functional gene based on 
the following observations. First, we found that only 31.9% of GPR42 alleles sequenced contained the 
R174W polymorphism. Second, the most common GPR42 haplotype (50.6%) differed from FFAR3 by 
just a single residue at the extreme C-terminus (S346N). Third, processed mRNA coding for GPR42 was 
found in human sympathetic ganglia and colon. Fourth, a common polymorphism (A919G; 30.8%) in 
GPR42 that was absent from FFAR3 was seen in colon RNA-seq databases (Illumina Body Map 2.0). 
Fifth, the most common GPR42 variant (42.1.1) was functionally equivalent to FFAR3 (41.1) in terms 
of potency and efficacy when assayed for Ca2+ channel modulation in rat sympathetic neurons. Sixth, 
GPR42 variants containing the R174W polymorphism, including the current GPR42 reference sequence, 
displayed less potency (for C3) but equal efficacy in the sympathetic neuron Ca2+ channel assay. This is in 
contrast to previous work2 suggesting complete inactivity of the GPR42 reference sequence. The reasons 
for the discrepancy are unclear, however, the assays used were very different (e.g., yeast reporter, GTP-γ -S 
binding) which might account for the different outcomes.
Definitive evidence for GPR42 function requires detection of the protein product in tissue with func-
tional response to agonist. However, given the high degree of sequence identity, discrimination from 
FFAR3 will be challenging. Knockout of GPR42 or knock-in of a reporter construct might also provide 
important evidence. Unfortunately, GPR42 is only found in primates and thus common genetically alter-
able mammals (e.g., mice) are unsuitable. Newer genetic methodologies such as CRISPR/Cas9 allow 
genetic alteration in primates37, hence such experiments are feasible. In that regard, a sequence corre-
sponding to an apparent GPR42 ORF is present in the rhesus macaque genome (Assembly BGI CR_1.0/
rehMac3; Chr19: 41973858–41974878) that contains a single base deletion at nucleotide position 97. The 
predicted frame shift resulting from the deletion would likely inactivate the protein. Although the rhesus 
genome has limitations38, we have confirmed the presence of this deletion in five rhesus gDNA samples 
(of both Chinese and Indian origin; unpublished observation). Hence, based on current information, 
rhesus GPR42 is a genuine nonfunctional pseudogene.
Copy number polymorphism in GPR42. The initial description of the human GPR40–43 family17 
included sequencing of a cosmid clone, U62631, that appeared to be missing a region containing the 
GPR42 ORF. Another clone, AC002511, contained GPR42 and the authors proposed that this region 
might represent a polymorphic insert. Later, the reference human genome was shown to contain GPR42 
and this anomaly received little further attention. In fact, the U62631 entry was edited to end within 
the GPR42 3′ -UTR (Genbank: U62631.2). Ironically, we found evidence supporting a 12.5 kb deletion 
that conformed with the original U62631 sequence. The deletion likely occurred via NAHR within the 
FFAR3/GPR42 duplicated region — a common mechanism in tandem segmentally duplicated genes39–41. 
The deletion was quite common in our cohort accounting for 18.8% of the potential GPR42 alleles. A 
single sample, B02, was deleted in both GPR42 alleles and thus represented a GPR42 knockout.
We found confirmatory evidence, a 12 kb deletion structural variant (dbVar: esv2678346), in 1000 
genomes data. The deletion has a global frequency of 18.5% but showed large variation in cohorts from 
different ancestry (Fig. S3). Of interest, the deletion is absent from the Yoruba and Luhya populations 
(from Nigeria and Kenya, respectively) but well represented in cohorts of European ancestry. At present, 
there are no clinical assertions documented for this variant. The precise breakpoint(s) of the deletion 
is unclear because of the high sequence identity of the boundary regions. However the presence of 
FFAR3 haplotypes (Group 3) containing the S346N variation suggest that the deletion may have occurred 
within homologous regions of the FFAR3/GPR42 ORF thereby resulting in a chimeric FFAR3 with the 
C-terminus of GPR42. A recent study42 indicates that the GPR42 copy number may exceed two suggest-
ing additional complexity within this region.
Variation in FFAR3 and GPR42. The magnitude of sequence variation within FFAR3 was unex-
pected. The reference sequence (41.1; Genbank: NM_005304) accounted for only 30.4% of the alleles 
examined. The next 3 most frequent variants (41.2–41.4), accounting for an additional 52.7% of alleles, 
each contained a single residue alteration of unknown consequence. Variant 41.4 contains the D158N 
substitution that may produce constitutive activity19 while 41.8 contains the R174W substitution that 
appears to alter efficacy2 or potency (this study).
The number of variants identified for GPR42 was equally unexpected. The major sets of variants, 
referred to as S346N and Group 1, complicate the designation for GPR42. The most common variants 
(42.1.1–42.1.2) differ by only a single residue and our electrophysiological studies (Fig. 6) indicate similar 
function to FFAR3 (41.1). Conversely, the Group 1 variants are complex, the majority possessing 6–7 
non-synonymous polymorphisms. There are variable sites common to both FFAR3 and GPR42 sug-
gesting some form of gene conversion. Hence, the GPR42 polymorphisms may best be classified as a 
multisite variation rather than paralogous sequence variants43. The absolute conservation of the S346N 
variation in every GPR42 allele sequenced is a mystery. An orthologous variation does not appear in 
other primate FFAR3/GPR42 orthologs (unpublished observation) although appears to be present in 
Neanderthal44 and Denisovan45 genomes. The extreme C-terminal residue of Group A GPCRs does not 
usually dictate important functions except when part of a PDZ ligand46. FFAR3/GPR42, however, do 
not contain a canonical PDZ ligand C-terminal sequence. The finding that GPR42 variants contain-
ing the R174W polymorphism are functional was surprising and bolsters the case for abandonment of 
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the pseudogene categorization. Although constructs containing R174W were approximately 6-fold less 
potent for C3, the abundance of SCFA in the lumen of the colon47 would suggest that sufficient endog-
enous ligand exists to activate these variants.
Conclusion
FFAR3 has been implicated in energy metabolism, sympathetic function, diabetes, immune function, 
and interactions with the gut microbiota. A primate-specific segmental duplication produced a duplicon 
termed GPR42 which has received little attention after being classified as a pseudogene. Here, we present 
multiple lines of evidence indicating that the function of GPR42 needs to be consider in human studies. 
GPR42 is a complex multisite variant and is affected by a common deletion that results in copy number 
polymorphism. Together with the variation in FFAR3 uncovered here, there may be complex haplotypes 
and copy number variations, possibly specific to human subpopulations, that impact human health and 
well-being.
Methods
Molecular Biology. Human genomic DNA samples (B01-50) were a generous gift from David 
Goldman MD, NIH/NIAAA/LNG. The cohort was 87% Caucasian, 52% male, and physically healthy 
at the time of collection. Each participant had a physical examination and routine blood tests at the 
NIH Clinical Center which were all normal. Participants gave informed consent according to a human 
research protocol approved by the Human Research Committee of the National Institute on Alcohol 
Abuse and Alcoholism, NIH. Human genomic DNA from a Finnish population in the 1000 Genomes 
Collection was obtained from the Coriell Institute for Medical Research (MGP00001; https://www.cori-
ell.org). Human celiac ganglia and colon tissue samples were obtained from National Disease Research 
Interchange (NDRI, http://ndriresource.org). All samples were de-identified. The NDRI samples were 
determined “Not Human Subjects Research” by the NIH Office of Human Subjects Research Protections 
(OHSRP #19912).
Oligonucleotide primers were purchased from IDT. All subsequent primer positions with respect to 
both FFAR3 and GPR42 genomic sequences are illustrated in Fig. S4. Primer sets to differentially amplify 
human FFAR3 or GPR42 from genomic DNA were based on previously published sequences18:
FFAR3 5′ : 5′ -CCCCAGAGATAATCCTGCACCAGT-3′ ;
GPR42 5′ : 5′ -TACAGGTACTATGACAATCCCTGTTCTG-3′ ;
ORF 3′ : 5′ -GAGGAAGCGCCCTGAGGATGAC-3′ .
FFAR3 or GPR42 genomic fragments were amplified from 10–15 ng of genomic DNA template in a 
25 μ L reaction using Q5 polymerase Master mix (NEB). Reactions were assembled in 0.2 mL PCR tubes 
using an Eppendorf epMotion M5073 liquid handling robot. Cycling parameters were as follows: 1 hold 
at 98 °C for 30 s followed by 33 cycles at 98°C for 10 s, 62 °C for 10 s and 72 °C for 90 s, followed by a 
final extension at 72 °C for 120 s.
PCR products were either purified using the Qiafilter PCR Cleanup kit from Qiagen and sequenced 
(MacrogenUSA) or subcloned using the TOPO PCR blunt cloning kit (Life Technologies) and individual 
clones were sequenced. PCR fragments and individual subclones were sequenced using the following 
internal overlapping primers:
FFAR3/GPR42mFor: 5′ -GTGGAGGCAGCCAATGGCATGC-3′ 
FFAR3/GPR42mRev: 5′ -CAGTGGGTGGGCCACACTCAGG-3′ .
Sequence data was analyzed using Sequencher and MacVector.
Paired genotype and transcript data were obtained as follows: Celiac ganglia were obtained frozen in 
PBS. The colon sample was provided in Optimal Cutting Temperature (OCT) compound. Samples were 
thawed in Hank’s balanced salt solution (pH 7.4), trimmed to remove extraneous material, cut into small 
(~100 mg) pieces and placed in 1 mL of RNALater solution (Qiagen) in 1.5 mL microcentrifuge tubes. 
Stabilized tissue samples were placed at 4 °C overnight and then stored at − 20 °C until use. Prior to use, 
the 100 mg piece was removed from the RNALater and cut into two equivalent pieces. One piece was 
used for genomic DNA preparation with the DNeasy Blood & Tissue Kit (Qiagen) and the second for 
total RNA preparation using the RNeasy miniprep kit (Qiagen). For RNA, the tissue was homogenized 
by grinding with a glass rod directly in lysis buffer (RTL). Following total RNA isolation, RNA qual-
ity was assessed using the Agilent Bioanalyzer and cDNA was prepared using the QuantiTect Reverse 
Transcription Kit (Qiagen).
Amplification of transcripts from cDNA was performed with Q5 polymerase and the following 
primers:
FFAR3/GPR42ex1For: 5′ -GCATTTGGGGTCTCAAAGAAGC-3′ 
ORF 3′ : 5′ -GAGGAAGCGCCCTGAGGATGAC-3′ .
Primers were designed to flank the 200 bp intron located in the 5′ -UTR as a means of discriminating 
properly spliced transcripts from any contaminating genomic DNA. Cycling parameters were as follows: 
1 hold at 98 °C for 30 s followed by 33 cycles of 98 °C for 10 s, 62 °C for 10 s and 72 °C for 60 s, and a single 
hold at 72 °C for 120 s. PCR products were subcloned and sequenced as described above.
The following primers were used as controls for RNA/cDNA quality (actin) and neuronal identity of 
input cells (TH):
Human β -actin control primer set: 981bp amplicon
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hACTex1f: 5′ -CGACAACGGCTCCGGCATGTGC-3′ 
hACTex5r: 5′ -GTACTTGCGCTCAGGAGGAGC-3′ 
Human Tyrosine Hydroxylase control primer set: 859bp amplicon
hTHex6f: 5′ -GCAGGAAGCTGATTGCTGAG-3′ 
hTHex14r: 5′ - GTGTCCAGCTCATCCTGGAC-3′ 
Copy Number Variation assays were performed on a Step One Plus real time PCR instrument (ABI) 
in quadruplicate as per manufacturers directions (ABI-Life Technologies) with 20 ng of genomic DNA. 
TaqMan® copy number qPCR assay #Hs04030486_cn was chosen from inventoried assays based upon 
location within the putative deleted region. Results were analyzed with ABI CopyCaller™ software.
PCR validation of the absence of the putative deleted genomic region was detected using primers 
FFAR3 5′ described above and a primer unique to the genomic region downstream from hGPR42. (R3: 
5′ -GTGATTCTCTTGCCTCGGCATC-3′ ). This primer set generated an approximately 3 kb fragment if 
a deletion was detected. PCR reaction conditions (Q5 polymerase- NEB) were: 1 hold at 98 °C for 30 s 
followed by 33 cycles of 98 °C for 10 s, 62 °C for 10 s and 72 °C for 90 s followed by a final extension at 
72 °C for 120 s.
Superior cervical ganglion (SCG) neuron dissociation and nuclear microinjection. All ani-
mal studies were conducted in accordance to the National Institutes of Health’s Guidelines for Animal 
Care and Use. SCG neurons from adult (6–12 week old) male Wistar rats were dissected and dissoci-
ated as described previously48. Briefly, animals were anesthetized by CO2 inhalation and decapitated 
before dissection. Two SCG per rat were removed, desheathed, cut into small pieces, and incubated in 
modified Earles’ balanced salt solution (EBSS) containing 1.7 mg/mL collagenase (CLS4; Worthington 
Biochemical), 0.6 mg/mL trypsin (Worthington Biochemical) and 0.1 mg/mL DNase I at 36 °C for 1 hour 
in a water bath shaker rotating at 110 rpm. The EBSS was supplemented with 3.6 g/L d-glucose and 
10 mM HEPES. After incubation, neurons were mechanically dissociated by vigorously shaking the flask 
for 10 s. Neurons were centrifuged at 570 rpm for 6 min and resuspended in Minimum Essential Medium 
(MEM) supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin (Life Technologies, 
Grand Island, NY) twice. Neurons were plated on poly-l-lysine coated tissue culture dishes and main-
tained in a humidified 95% air/5% CO2 incubator at 37 °C.
Three to six hours after dissociation, plasmid cDNA constructs were injected directly into the nucleus 
of SCG neurons as described previously48,49. Briefly, cDNA was injected with an Eppendorf FemtoJet 
microinjector and 5171 micromanipulator (Eppendorf, Hauppauge, NY) using an injection pressure and 
duration of 140–160 hPa and 0.3 s, respectively. Mammalian expression vectors encoding variants of 
FFAR3 or GPR42 were injected at a concentration of 10–100 ng/μ L along with 5 ng/μ L EGFP cDNA 
(Clontech, Mountain View, CA) to identify successfully injected neurons. Following injections, neurons 
were incubated overnight at 37 °C and electrophysiological experiments were performed the following 
day.
Electrophysiology. Ca2+ -channel currents were recorded using a patch-clamp amplifier (Axopatch 
200B, Molecular Devices, Sunnyvale, CA) and conventional whole-cell patch-clamp techniques50. Patch 
electrodes were pulled from borosilicate glass capillaries (1.65 mm OD, 1.20 mm ID, King Precision Glass, 
Claremont, CA) using a Model P-97 micropipette puller (Sutter Instrument, Novato, CA). The patch elec-
trodes were coated with silicone elastomer (Sylgard 184, Dow Corning, Midland, MI) and fire-polished. 
A Ag/AgCl pellet connected to the bath solution via a 0.15 M NaCl/agar bridge was used as a ground. 
Voltage protocol generation and data acquisition were performed using a custom written program using 
Igor Pro software (version 6, WaveMetrics, Portland, OR). Cell membrane capacitance was cancelled 
and series resistance was compensated (> 85% prediction and correction; lag set to 5 μ s). Current traces 
were filtered at 2 kHz (− 3 dB; 4-pole Bessel), digitized at 10 kHz with a 16-bit analog-to-digital converter 
board (ITC-18, HEKA, Bellmore, NY) and stored on the computer for later analyses. To measure mod-
ulation of Ca2+ -channels following G protein activation, a double-pulse protocol consisting of two 25 
ms test pulses to + 10 mV separated by a 50 ms conditioning pulse to + 80 mV51 was evoked every 10 s 
from a holding potential of − 80 mV.
For recording Ca2+ currents, patch pipettes were filled with an internal solution containing (in mM) 
120 N-methyl-d-glucamine, 20 tetraethylammonium hydroxide (TEA-OH), 11 EGTA, 10 HEPES, 10 
sucrose, 1 CaCl2, 14 Tris-creatine phosphate, 4 MgATP and 0.3 Na2GTP, pH 7.2 with methanesulfonic 
acid. External Ca2+ current recording solution consisted of (in mM) 140 methanesulfonic acid, 145 
TEA-OH, 10 HEPES, 10 glucose, 10 CaCl2 and 0.0003 tetrodotoxin (TTX), pH 7.4 with TEA-OH.
A range of propionate (C3) solution concentrations was applied directly onto neurons using a 
custom-made gravity-fed perfusion system with separate perfusion lines feeding into a custom designed 
7-bore glass capillary tube (manufactured by VitroCom, Mountain Lakes, NJ) connected to a fused silica 
capillary tube. A constant flow of external solution was applied onto cells during baseline recordings 
and switched to a C3 solution during test applications to avoid flow-induced artifacts. All C3 solutions 
were diluted to final concentrations from a 1 M stock solution on the day of experiment and the pH was 
checked (pH 7.4–7.45). All recordings were performed at room temperature (20–24 °C).
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Data analysis and statistical testing. Igor Pro software was used to analyze current traces and sta-
tistical tests were performed with GraphPad Prism 6 for Mac OS X (GraphPad Software, La Jolla, CA). 
Ca2+ current amplitude was measured isochronally 10 ms after the initiation of a test pulse to + 10 mV. 
The facilitation ratio (FR) was determined as the ratio of postpulse to prepulse Ca2+ current. Individual 
data points or the mean ± SEM were represented on graphs. Concentration-response curves were fit 
using non-linear regression (GraphPad Prism 6) to a 2-parameter equation:
= /( + ) ( )−Y Y 1 10 1max
EC XLog 50
where Y is the agonist induced Ca2+ current inhibition, Ymax is the maximal inhibition, EC50 is the agonist 
concentration at half-maximal response, and X is log[agonist]. Statistical analysis between three or more 
groups was performed using a one-way analysis of variance (ANOVA) test followed by a Bonferroni’s 
multiple comparisons test. P-values < 0.05 was considered statistically significant.
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